Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases

NCT ID: NCT01767935

Last Updated: 2018-11-14

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 1 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2014-12-31

Brief Summary

This pilot clinical trial studies cryosurgery and radiation therapy in treating patients with painful bone metastases. Cryosurgery kills tumor cells by freezing them. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Giving cryosurgery together with radiation therapy may kill more tumor cells

Detailed Description

PRIMARY OBJECTIVES:

I. To assess the potential for efficacy and safety of combining percutaneous computed tomography (CT)-guided cryoablation and radiotherapy for the palliation of osseous metastases.

OUTLINE:

Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 24 hours and weeks 1-2, 4, 12, 18, and 24.

Conditions

Bone Metastases; Pain

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment (cryosurgery and radiation therapy)

Patients undergo cryosurgery. Beginning 2 weeks later, patients undergo 1, 10, or 15 fractions of radiation therapy 5 days per week for 1-3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.

Group Type: EXPERIMENTAL

cryosurgery

Intervention Type: PROCEDURE

Undergo cryosurgery

radiation therapy

Intervention Type: RADIATION

Undergo radiation therapy

quality-of-life assessment

Intervention Type: PROCEDURE

Ancillary studies

Interventions

cryosurgery

Undergo cryosurgery

Intervention Type: PROCEDURE

radiation therapy

Undergo radiation therapy

Intervention Type: RADIATION

quality-of-life assessment

Ancillary studies

Intervention Type: PROCEDURE

Other Intervention Names

cryoablation; cryosurgical ablation; irradiation; radiotherapy; therapy, radiation; quality of life assessment

Eligibility Criteria

Inclusion Criteria

• Pathologically (histologically or cytologically) confirmed metastatic disease with a new tumor involving or abutting bone that has the clinical and imaging features of metastatic disease

• If the nature of the metastatic disease has been previously documented, index tumor to be treated does not require further documentation (i.e., biopsy)
• Current analgesic therapies have failed (worst pain of 4 or above as measured by Brief Pain Inventory [BPI], despite analgesic therapy) OR the subject is experiencing intolerable side effects that preclude analgesic use (resulting in pain of 4 or above, as measured by BPI)
• Pain must be from one or two painful metastatic sites in the bone (additional less painful metastatic sites may be present)

• Pain from the reported one or two metastatic sites must correlate with an identifiable tumor on CT, magnetic resonance imaging (MRI), or ultrasound (US) imaging
• Metastatic tumors must be amenable to cryoablation with CT or MRI
• If the index tumor is in the spine, there must be an intact cortex between the mass and the spinal canal and exiting nerve roots
• Patients must have stable use of hormonal therapy for two weeks prior to study registration and two weeks prior to cryoablation procedure)
• Stable use of pain medications (no changes within two weeks of cryoablation procedure)
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Life expectancy >= 2 months
• Platelets > 50,000/mm^3
• International normalized ratio (INR) >= 1.5
• Patients may not have any debilitating medical or psychiatric illness that would preclude giving informed consent or receiving optimal treatment and follow-up
• Patients who are taking antiplatelet or anticoagulation medication (e.g., aspirin, ibuprofen, low molecular weight heparin [LMWH] preparations) must be able to discontinue such treatment prior to the cryoablation procedure for an appropriate amount of time; at least 5 days should be allowed after discontinuation of aspirin, Coumadin, clopidogrel, and dipyridamole; at least 12 hours should be allowed after discontinuation of LMWH preparations
• Patients must be clinically suitable for cryoablation therapy
• Patients must be clinically suitable for radiation therapy
• Patients must be able to understand and willing to sign a written informed consent document

Exclusion Criteria

• Patients with a diagnosis of leukemia, lymphoma, or myeloma
• Patients with a tumor involving a weight-bearing long bone of the lower extremity with the tumor causing > 50% loss of cortical bone
• Patients who have undergone prior ablation treatment or radiation therapy of the index tumor
• Patients who have received chemotherapy within 14 days prior to and 14 days after cryoablation procedure
• Index tumor(s) causing clinical or radiographic evidence of spinal cord or cauda equine compression/effacement
• Anticipated treatment of the index tumor that would require iceball formation within 1.0 cm of the spinal cord, brain, other critical nerve structure, large abdominal vessel such as the aorta or inferior vena cava (IVC), bowel, or bladder
• Any prior surgery at the proposed treatment site OR any prior surgery involving the cryoablation-treated tumor
• Index tumor involves the skull (treatment of other painful tumors in subjects with skull tumors is not excluded)
• Patients with uncontrolled coagulopathy or bleeding disorders
• Patients who are pregnant, nursing, or who wish to become pregnant during the study
• Patients with active, uncontrolled infection
• Patients with serious medical illnesses, including any of the following: uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction, cerebrovascular event within six months prior to study entry
• Patients who are concurrently participating in any other experimental studies that could affect the primary endpoint of this study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Cancer Institute (NCI)

NIH

Sponsor Role: collaborator

Endocare, Inc.

INDUSTRY

Sponsor Role: collaborator

Wake Forest University Health Sciences

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

David Childs

Role: PRINCIPAL_INVESTIGATOR

Wake Forest University Health Sciences

Locations

Comprehensive Cancer Center of Wake Forest University

Winston-Salem, North Carolina, United States

Countries

United States

Other Identifiers

NCI-2012-02087

Identifier Type: REGISTRY

Identifier Source: secondary_id

P30CA012197

Identifier Type: NIH

Identifier Source: secondary_id

View Link

CCCWFU 97212

Identifier Type: OTHER

Identifier Source: secondary_id

IRB00020528

Identifier Type: -

Identifier Source: org_study_id